<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690270</url>
  </required_header>
  <id_info>
    <org_study_id>A095470</org_study_id>
    <secondary_id>277675</secondary_id>
    <nct_id>NCT04690270</nct_id>
  </id_info>
  <brief_title>Sumatriptan and Glucose</brief_title>
  <official_title>Effects of Serotonin Receptor Agonism on Blood Glucose Lowering: Proof of Concept in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the proof of concept for a brain serotonin pathway&#xD;
      controlling blood glucose control in humans. We will examine whether activation of serotonin&#xD;
      receptors by a single dose of sumatriptan (a drug used for the treatment of migraine) can&#xD;
      lead to short term changes in blood glucose homeostasis. Thus far, this has been shown only&#xD;
      in animal models but no study in humans has directly investigated this research question.&#xD;
&#xD;
      Briefly, in this study we will give a single dose of sumatriptan (100 mg) to each participant&#xD;
      in a small sample (10 to 12) of overweight or obese, otherwise healthy humans. It will take&#xD;
      place in the Translational Research Facility which is embedded in the Cambridge University&#xD;
      Hospitals NHS Foundation Trust. The research staff have extensive experience and expertise in&#xD;
      the procedures which will be used. The study will involve a screening visit and 2 subsequent&#xD;
      visits at which sumatriptan/placebo will be taken and the glucose metabolism will be assessed&#xD;
      using a Botnia clamp (3h procedure involving insulin and glucose infusions given&#xD;
      intravenously with frequent blood sampling to assess insulin secretion and sensitivity).&#xD;
      There will be about 60 days between screening visit and the last visit. The entire study&#xD;
      (including the recruitment and data analysis) is expected to complete in about 12 months.&#xD;
&#xD;
      If sumatriptan alters glucose control, this might support future testing in disease models&#xD;
      i.e. people with type 1 diabetes (T1D) and/or type 2 diabetes (T2D). Ultimately, if&#xD;
      successful, either sumatriptan could be repurposed and/or other drugs from this group&#xD;
      (triptans) could be developed for diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 4, 2021</start_date>
  <completion_date type="Anticipated">June 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>1 to 4 weeks</time_frame>
    <description>Change in M-value from the hyperinsulinaemic euglycaemic clamp from visit 2 to visit 3 between sumatriptan and placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>1 to 4 weeks</time_frame>
    <description>Change in first phase insulin response from the intravenous glucose tolerance test from visit 2 to visit 3 between sumatriptan and placebo</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Sumatriptan 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Given the cross-over design all participants will receive both sumatriptan (100 mg, single dose) and placebo in a random order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan 100 mg</intervention_name>
    <description>Single dose Sumatriptan 100 mg</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sumatriptan 100 mg</arm_group_label>
    <other_name>Example of a brand name for sumatriptan: Migratan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Being able to provide a written informed consent&#xD;
&#xD;
          2. Age between 18 and 65 years&#xD;
&#xD;
          3. Body Mass Index (BMI) ≥25 kg/m2 and &lt;30 kg/m2 for non-Asian individuals and BMI≥23&#xD;
             kg/m2 and &lt;25 kg/m2 for Asian individuals according to the BMI classification by the&#xD;
             World Health Organization (WHO)&#xD;
&#xD;
          4. HbA1C&lt;48 mmol/mol at screening&#xD;
&#xD;
          5. Subject must not use any regular prescribed medications (this excludes simple&#xD;
             analgesia used as needed)&#xD;
&#xD;
          6. Subject must not use any over the counter supplements targeting metabolism&#xD;
&#xD;
          7. Subject must not have any acute or chronic disease which in the opinion of the&#xD;
             investigator may affect the study outcome&#xD;
&#xD;
          8. Subject must not be a current smoker&#xD;
&#xD;
          9. No history of substance abuse or excess alcohol consumption (&gt;14 units/week)&#xD;
&#xD;
         10. Women of childbearing age must have a negative pregnancy test at screening and must&#xD;
             not be breastfeeding&#xD;
&#xD;
         11. Women of childbearing age who are sexually active with a male partner must use highly&#xD;
             effective contraceptive methods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any regular medications&#xD;
&#xD;
          2. Use of illicit drugs&#xD;
&#xD;
          3. Use of any over the counter supplements affecting metabolism&#xD;
&#xD;
          4. Diagnosis of any acute / chronic disease&#xD;
&#xD;
          5. Current smoking or excess alcohol consumption (&gt;14 units/week)&#xD;
&#xD;
          6. Current pregnancy or lactation&#xD;
&#xD;
          7. Abnormal findings on physical exam or routine blood tests at screening (full blood&#xD;
             count, urea and electrolytes, HbA1C, liver function tests)&#xD;
&#xD;
          8. Concurrent participation in another trial with an investigational product&#xD;
&#xD;
          9. History of anaphylaxis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Evans</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Metabolic Science, Hills Road, CB2 0QQ, Cambridge, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rajna Golubic, MD, PhD</last_name>
    <phone>01223748471</phone>
    <email>rg380@medschl.cam.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Kennet, MD, FRCP</last_name>
    <phone>01223748471</phone>
    <email>jk605@cam.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rajna Golubic</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Rajna Golubic, MD, PhD</last_name>
      <phone>01223748471</phone>
      <email>rg380@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jane Kennet</last_name>
      <phone>01223748471</phone>
      <email>jk605@cam.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Evans, MD, FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 27, 2020</study_first_submitted>
  <study_first_submitted_qc>December 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>December 27, 2020</last_update_submitted>
  <last_update_submitted_qc>December 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Rajna Golubic</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>glucose homeostasis</keyword>
  <keyword>insulin secretion</keyword>
  <keyword>insulin sensitivity</keyword>
  <keyword>serotonin agonism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

